Rare diseases
FDA Resumes Approval of Sarepta Therapeutics’ Duchenne Therapy for Younger Patients: What You Need to Know
The FDA has made a significant announcement regarding Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy. Effective Monday, the agency ... Read more
Sarepta Therapeutics’ Duchenne Therapy: What an FDA Official Says About Its Challenging Road to Market
Sarepta Therapeutics is facing tough challenges with its gene therapy for Duchenne muscular dystrophy, called Elevidys. This treatment is currently ... Read more
Breaking News: Sarepta Therapeutics Suspends Duchenne Gene Therapy Shipments—What This Means for Patients
Sarepta Therapeutics announced it will stop shipments of Elevidys, a gene therapy for Duchenne muscular dystrophy, following a request from ... Read more
Sarepta Therapeutics Cuts One-Third of Workforce: What This Means for the Future of the Company
Sarepta Therapeutics has recently made significant cutbacks, laying off about 500 employees, which is more than one-third of its workforce. ... Read more
